Patents by Inventor Markus Haake

Markus Haake has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GDF-15 AS A DIAGNOSTIC MARKER TO PREDICT THE CLINICAL OUTCOME OF A TREATMENT WITH IMMUNE CHECKPOINT BLOCKERS
    Publication number: 20260140123
    Abstract: The present invention relates to methods for predicting the probability of a treatment response of a human cancer patient to an immune checkpoint blocker treatment e.g. with anti PD-1, and to methods for predicting the probability of survival of a human cancer patient following an immune checkpoint blocker treatment, and to apparatuses and kits which can be used in these methods.
    Type: Application
    Filed: October 22, 2025
    Publication date: May 21, 2026
    Inventors: Jörg Wischhusen, Markus Haake, Reinhard Dummer, Matthias Mehling
  • Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers
    Patent number: 12629418
    Abstract: The present invention relates to uses of inhibitors of human Growth and Differentiation Factor 15 (GDF-15), and to combined uses of such inhibitors with immune checkpoint blockers, in the treatment of solid cancers.
    Type: Grant
    Filed: August 30, 2022
    Date of Patent: May 19, 2026
    Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG
    Inventors: Jörg Wischhusen, Markus Haake, Reinhard Dummer, Matthias Mehling, Tina Schäfer, Martina Selle
  • ANTI-GDF15 ANTIBODY AND A DOSAGE REGIMEN FOR THE TREATMENT OF CANCER
    Publication number: 20260055172
    Abstract: The present invention relates to an anti-GDF15 antibody and to a dosage regimen for the treatment of cancer in a human patient using the anti-GDF15 antibody. The present inventors identified a mechanism by which GDF-15 blocks adhesion and transgression of predominantly T-lymphocytes into tissues. Hence, a novel treatment approach has been established by the present invention that facilitates effector T cell entry into tumor tissue upon blockage of GDF-15 using the antibody of the present invention thereby allowing the treatment of cancer in human patients.
    Type: Application
    Filed: November 6, 2025
    Publication date: February 26, 2026
    Inventors: Eugen Leo, Markus Haake, Jörg Wischhusen, Virginie Le Brun, Susanne Jörg, Manfred Rüdiger
  • Anti-GDF15 antibody and a dosage regimen for the treatment of cancer
    Patent number: 12497447
    Abstract: The present invention relates to an anti-GDF15 antibody and to a dosage regimen for the treatment of cancer in a human patient using the anti-GDF15 antibody. The present inventors identified a mechanism by which GDF-15 blocks adhesion and transgression of predominantly T-lymphocytes into tissues. Hence, a novel treatment approach has been established by the present invention that facilitates effector T cell entry into tumor tissue upon blockage of GDF-15 using the antibody of the present invention thereby allowing the treatment of cancer in human patients.
    Type: Grant
    Filed: May 15, 2025
    Date of Patent: December 16, 2025
    Assignees: CatalYm GmbH, JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG
    Inventors: Eugen Leo, Markus Haake, Jörg Wischhusen, Virginie Le Brun, Susanne Jörg, Manfred Rüdiger
  • GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
    Patent number: 12473354
    Abstract: The present invention relates to methods for predicting the probability of a treatment response of a human cancer patient to an immune checkpoint blocker treatment e.g. with anti PD-1, and to methods for predicting the probability of survival of a human cancer patient following an immune checkpoint blocker treatment, and to apparatuses and kits which can be used in these methods.
    Type: Grant
    Filed: January 20, 2022
    Date of Patent: November 18, 2025
    Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG
    Inventors: Jörg Wischhusen, Markus Haake, Reinhard Dummer, Matthias Mehling
  • ANTI-GDF15 ANTIBODY AND A DOSAGE REGIMEN FOR THE TREATMENT OF CANCER
    Publication number: 20250282858
    Abstract: The present invention relates to an anti-GDF15 antibody and to a dosage regimen for the treatment of cancer in a human patient using the anti-GDF15 antibody. The present inventors identified a mechanism by which GDF-15 blocks adhesion and transgression of predominantly T-lymphocytes into tissues. Hence, a novel treatment approach has been established by the present invention that facilitates effector T cell entry into tumor tissue upon blockage of GDF-15 using the antibody of the present invention thereby allowing the treatment of cancer in human patients.
    Type: Application
    Filed: May 15, 2025
    Publication date: September 11, 2025
    Inventors: Eugen Leo, Markus Haake, Jörg Wischhusen, Virginie Le Brun, Susanne Jörg, Manfred Rüdiger
  • ANTI-GDF15 ANTIBODY AND A DOSAGE REGIMEN FOR THE TREATMENT OF CANCER
    Publication number: 20240043517
    Abstract: The present invention relates to an anti-GDF15 antibody and to a dosage regimen for the treatment of cancer in a human patient using the anti-GDF15 antibody. The present inventors identified a mechanism by which GDF-15 blocks adhesion and transgression of predominantly T-lymphocytes into tissues. Hence, a novel treatment approach has been established by the present invention that facilitates effector T cell entry into tumor tissue upon blockage of GDF-15 using the antibody of the present invention thereby allowing the treatment of cancer in human patients.
    Type: Application
    Filed: May 10, 2023
    Publication date: February 8, 2024
    Inventors: Eugen LEO, Markus HAAKE, Jörg WISCHHUSEN, Virginie LE BRUN, Susanne JÖRG, Manfred RÜDIGER
  • COMBINATION THERAPY USING INHIBITORS OF HUMAN GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15) AND IMMUNE CHECKPOINT BLOCKERS
    Publication number: 20230093412
    Abstract: The present invention relates to uses of inhibitors of human Growth and Differentiation Factor 15 (GDF-15), and to combined uses of such inhibitors with immune checkpoint blockers, in the treatment of solid cancers.
    Type: Application
    Filed: August 30, 2022
    Publication date: March 23, 2023
    Inventors: Jörg WISCHHUSEN, Markus Haake, Reinhard Dummer, Matthias Mehling, Tina SCHÄFER, Martina Selle
  • Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers
    Patent number: 11464856
    Abstract: The present invention relates to uses of inhibitors of human Growth and Differentiation Factor 15 (GDF-15), and to combined uses of such inhibitors with immune checkpoint blockers, in the treatment of solid cancers.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: October 11, 2022
    Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT Würzburg
    Inventors: Jörg Wischhusen, Markus Haake, Reinhard Dummer, Matthias Mehling, Tina Schäfer, Martina Selle
  • GDF-15 AS A DIAGNOSTIC MARKER TO PREDICT THE CLINICAL OUTCOME OF A TREATMENT WITH IMMUNE CHECKPOINT BLOCKERS
    Publication number: 20220242942
    Abstract: The present invention relates to methods for predicting the probability of a treatment response of a human cancer patient to an immune checkpoint blocker treatment e.g. with anti PD-1, and to methods for predicting the probability of survival of a human cancer patient following an immune checkpoint blocker treatment, and to apparatuses and kits which can be used in these methods.
    Type: Application
    Filed: January 20, 2022
    Publication date: August 4, 2022
    Inventors: Jörg WISCHHUSEN, Markus Haake, Reinhard Dummer, Matthias Mehling
  • GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
    Patent number: 11262360
    Abstract: The present invention relates to methods for predicting the probability of a treatment response of a human cancer patient to an immune checkpoint blocker treatment e.g. with anti PD-1, and to methods for predicting the probability of survival of a human cancer patient following an immune checkpoint blocker treatment, and to apparatuses and kits which can be used in these methods.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: March 1, 2022
    Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG
    Inventors: Jörg Wischhusen, Markus Haake, Reinhard Dummer, Matthias Mehling
  • Targets of
    Patent number: 10682404
    Abstract: The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: June 16, 2020
    Inventors: Simon Urwyler, Markus Haake, Michael Rudolf
  • Targets of
    Patent number: 10603372
    Abstract: The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: March 31, 2020
    Inventors: Simon Urwyler, Markus Haake, Michael Rudolf
  • Targets of
    Patent number: 10603373
    Abstract: The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: March 31, 2020
    Inventors: Simon Urwyler, Markus Haake, Michael Rudolf
  • NOVEL TARGETS OF ACINETOBACTER BAUMANNII
    Publication number: 20200016258
    Abstract: The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.
    Type: Application
    Filed: September 25, 2019
    Publication date: January 16, 2020
    Inventors: Simon Urwyler, Markus Haake, Michael Rudolf
  • Targets of acinetobacter baumannii
    Patent number: 10463727
    Abstract: The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: November 5, 2019
    Inventors: Simon Urwyler, Markus Haake, Michael Rudolf
  • Targets of acinetobacter baumannii
    Patent number: 10420828
    Abstract: The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: September 24, 2019
    Inventors: Simon Urwyler, Markus Haake, Michael Rudolf
  • Targets of
    Patent number: 10398767
    Abstract: The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: September 3, 2019
    Inventors: Simon Urwyler, Markus Haake, Michael Rudolf
  • COMBINATION THERAPY USING INHIBITORS OF HUMAN GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15) AND IMMUNE CHECKPOINT BLOCKERS
    Publication number: 20190160169
    Abstract: The present invention relates to uses of inhibitors of human Growth and Differentiation Factor 15 (GDF-15), and to combined uses of such inhibitors with immune checkpoint blockers, in the treatment of solid cancers.
    Type: Application
    Filed: September 30, 2016
    Publication date: May 30, 2019
    Inventors: Jörg WISCHHUSEN, Markus HAAKE, Reinhard DUMMER, Matthias MEHLING, Tina SCHÄFER, Martina SELLE
  • NOVEL TARGETS OF ACINETOBACTER BAUMANNII
    Publication number: 20190000955
    Abstract: The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.
    Type: Application
    Filed: September 7, 2018
    Publication date: January 3, 2019
    Inventors: Simon Urwyler, Markus Haake, Michael Rudolf